GlycoMimetics, Inc. is developing specialized compounds
to treat orphan diseases.

newS

GlycoMimetics Announces Two Key Leadership Promotions

Progress of GlycoMimetics'
Novel Compounds Highlighted at
2011 Annual Meeting of the American Society of Hematology

GlycoMimetics and Pfizer Enter into Licensing Agreement for Drug Candidate Currently in Development to Treat Patients Experiencing Vaso-occlusive Crisis Associated with Sickle Cell Disease

GlycoMimetics Highlights Clinical, Preclinical Progress with GMI-1070 in Sickle Cell Crisis at ASH 2010

GlycoMimetics Participates in Sickle Cell Information Session on Capitol Hill

 
Information for Sickle Cell Disease Community Organizations »
OUR LEAD DRUG CANDIDATES

GMI-1070

GlycoMimetics's lead anti-inflammatory compound, GMI-1070, is in Phase 2 clinical trials evaluating its use in patients with vaso-occlusive crisis of sickle cell disease. The drug inhibits a key early step in the inflammatory process leading to leukocyte adhesion and recruitment to inflamed tissue.

More about GMI-1070 »

Compounds Targeting E-selectin and CXCR4

GlycoMimetics has a family of compounds targeting the overlapping pathways of E-selectin and CXCR4. These compounds hold promise for treatment of blood cancers and certain inflammatory conditions.

What are glycomimetics? »

Site Map | Copyright © 2012 | Contact Us